US stock futures dip as Nvidia earnings spark little cheer
CHICAGO—Eric Lefkofsky, CEO and Chairman of Tempus AI , Inc. (NASDAQ:TEM), has recently sold a significant portion of his holdings in the company. According to a filing with the Securities and Exchange Commission, Lefkofsky sold a total of 238,082 shares of Class A Common Stock over three days, from February 5 to February 7, 2025. The transactions were executed at prices ranging from $67.01 to $69.32 per share, amounting to a total value of approximately $16.2 million. The stock has shown remarkable momentum, with a YTD return of over 92% according to InvestingPro data.
The sales were conducted to cover statutory tax withholding obligations related to the vesting of restricted stock units, as mandated by Tempus AI’s equity incentive plans. This type of transaction, known as a "sell to cover," is not considered a discretionary sale by Lefkofsky.
Following these transactions, Lefkofsky holds 5,293,005 shares directly. Additionally, he maintains indirect ownership of shares through various entities, including Gray Media, LLC and the Lefkofsky Family Foundation, among others.
Tempus AI, based in Chicago, specializes in computer programming and data processing services, continuing to attract attention in the tech sector.
In other recent news, Tempus AI has seen several significant developments. The company has upgraded its stock rating and raised the price target to $74, according to TD Cowen. This upgrade follows Tempus AI’s acquisition of Ambry Genetics, a profitable germline testing laboratory with over $300 million in revenue. Analysts from TD Cowen believe this acquisition will enhance Tempus AI’s product offerings and enable it to enter new markets.
Additionally, Tempus AI has launched a personal health concierge app called Olivia. This app aims to aggregate patient health data from over 1,000 health systems, providing actionable AI-driven insights. The company’s CEO, Eric Lefkofsky, believes that tools like Olivia are becoming indispensable for patients to manage their healthcare journey.
Furthermore, Tempus AI has entered into a multi-year agreement with Genialis to validate new RNA-based biomarker algorithms. This collaboration is expected to advance the development of WEE1 therapies and explore other DDR (NYSE:SITC) targets. These recent developments highlight Tempus AI’s strategic moves to enhance its capabilities and solidify its position in the precision medicine and patient care sectors.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.